<DOC>
	<DOCNO>NCT00003293</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether SU-101 effective procarbazine treat patient glioblastoma multiforme . PURPOSE : Randomized phase III trial compare effectiveness SU-101 procarbazine treat patient glioblastoma multiforme recur .</brief_summary>
	<brief_title>SU-101 Compared With Procarbazine Treating Patients With Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : I . Compare median survival patient glioblastoma multiforme first relapse treat intravenous leflunomide ( SU101 ) administer load dose weekly maintenance therapy versus oral , single-agent procarbazine administer daily 28 day every 56 day . II . Compare median time progression regimens patient . III . Assess objective response patient . IV . Assess safety SU101 give schedule . V. Describe health-related quality life patient . OUTLINE : This randomize , open label , multicenter study . Patients stratify accord performance status ( Karnofsky 60-80 % vs 90-100 % ) , age ( le 50 v 50 ) , time initial diagnosis recurrence ( 6 month great v less 6 month ) . Patients randomize one two treatment arm . Arm I : Patients receive leflunomide ( SU101 ) IV 6 hour daily day 1-4 , 4-8 day later , weekly thereafter total 4 load dose infusion six maintenance infusion course 1 . Patients receive 7 weekly maintenance infusion SU101 course thereafter . Treatment repeat every 8 week . Arm II : Patients receive procarbazine orally twice daily 4 week . Treatment repeat every 8 week . All patient complete health-related quality-of-life questionnaire every 8 week study withdrawal . Treatment course continue maximum 1 year absence unacceptable toxicity disease progression . Patients follow every 2 month , begin 30 day study completion . PROJECTED ACCRUAL : A maximum 380 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven refractory recurrent supratentorial glioblastoma multiforme Bidimensionally measurable , enhance residual disease T1weighted gadoliniumenhanced MRI require within 15 day prior treatment Stable dose corticosteroid require least 7 day prior scan PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 75,000/mm3 Hemoglobin least 9 g/dL without blood transfusion 15 day prior treatment Hepatic : AST/SGOT great 3 time upper limit normal ( ULN ) Bilirubin le 1.5 time ULN Renal : Creatinine great 2 mg/dL OR Creatinine clearance least 40 mL/min Other : Not allergic etoposide Effective contraception require fertile patient Negative serum pregnancy test require fertile woman No acute chronic medical psychiatric condition PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior leflunomide ( SU101 ) therapy No one prior singleagent combination systemic chemotherapy regimen initial disease Radiosensitizer ( ) concurrent radiotherapy allow addition chemotherapy primary disease At least 6 week since nitrosourea mitomycin At least 2 week since vincristine No prior singleagent procarbazine At least 4 week since chemotherapy No concurrent chemotherapy agent Endocrine therapy : No concurrent hormone therapy ( except medroxyprogesterone acetate appetite stimulation ) Less 4 week prior hormonal therapy ( tamoxifen retinoids ) fail one prior chemotherapy regimen Radiotherapy : Prior conventional radiotherapy initial disease require No one prior course radiotherapy At least 8 week since radiotherapy No prior interstitial radiotherapy No concurrent radiotherapy Surgery : Maximally feasible resection initial disease require No two resection permit At least 1 week since surgery and/or biopsy disease No prior interstitial radiotherapy implant BCNUwafers No concurrent surgery ( include resection , stereotactic surgery interstitial implant ) Other : No concurrent investigational agent At least 4 week since prior investigational agent At least 1 week since cholestyramine monoamine oxidase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>